Pricing Log in Create free account

DiaMedica Therapeutics, Inc. (DMAC) vs Neurogene Inc. (NGNE)

DiaMedica Therapeutics, Inc. and Neurogene Inc. are both Biotechnology companies. DiaMedica Therapeutics, Inc. and Neurogene Inc. are of similar size ($520.4M and $520.3M). Across the 8 metrics below, Neurogene Inc. leads on 5 and DiaMedica Therapeutics, Inc. on 3.

Valuation

Metric DMAC NGNE Biotechnology median
P/E n/m n/m 10.85
P/S n/m n/m 9.49
P/B 13.55 2.69 2.18
Price to free cash flow n/m n/m 25.85
EV/EBITDA n/m n/m 0.70
EV/Sales n/m n/m 8.99
Earnings yield (7.47%) (19.40%) (31.76%)
Free cash flow yield (6.07%) (15.00%) (21.84%)

Profitability

Metric DMAC NGNE Biotechnology median
Gross margin 0.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (114.62%) (45.32%) (50.82%)
Return on assets (98.18%) (41.02%) (46.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DMAC NGNE Biotechnology median
Revenue growth (TTM) — — 6.96%
EPS growth (last fiscal year) (16.67%) 0.93% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DMAC NGNE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.72 10.64 4.84
Net debt to EBITDA 1.70 2.57 1.01

Dividend

Metric DMAC NGNE Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric DMAC NGNE Biotechnology median
Market cap 520.38m 520.30m 163.56m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack